FDA Approves Revolution Medicines' RASONQUE as First Targeted RAS Inhibitor
Question
FDA Approves Revolution Medicines' RASONQUE as First Targeted RAS Inhibitor
Direct answer
The U.S. Food and Drug Administration granted marketing approval to Revolution Medicines for RASONQUE (daraxonrasib). The drug is authorized for patients with metastatic pancreatic adenocarcinoma who progressed on prior therapy or cannot tolerate multiagent chemotherapy. The regulatory clearance marks a significant milestone in oncology by establishing the first commercial broad RAS-targeted inhibitor, validating the company's RAS(ON) inhibitor pipeline. — bullish pressure on XBI.
- Original publisher
- Market Ontology
- Evidence through
- 2026-08-26
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “FDA Approves Revolution Medicines' RASONQUE as First Targeted RAS Inhibitor”, revision 1, evidence through 2026-08-26. https://marketontology.com/catalysts/2026-08-26/fda-approves-revolution-medicines-rasonque-as-first-targeted-ras-inhibitor-50d12a
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| XBI | ▲Bull | 1–5 days | Policy Shift | 54 |
FDA Approves Revolution Medicines' RASONQUE as First Targeted RAS Inhibitor
The U.S. Food and Drug Administration granted marketing approval to Revolution Medicines for RASONQUE (daraxonrasib). The drug is authorized for patients with metastatic pancreatic adenocarcinoma who progressed on prior therapy or cannot tolerate multiagent chemotherapy. The regulatory clearance marks a significant milestone in oncology by establishing the first commercial broad RAS-targeted inhibitor, validating the company's RAS(ON) inhibitor pipeline. — bullish pressure on XBI.
The U.S. Food and Drug Administration granted marketing approval to Revolution Medicines for RASONQUE (daraxonrasib). The drug is authorized for patients with metastatic pancreatic adenocarcinoma who progressed on prior therapy or cannot tolerate multiagent chemotherapy. The regulatory clearance marks a significant milestone in oncology by establishing the first commercial broad RAS-targeted inhibitor, validating the company's RAS(ON) inhibitor pipeline.
- SummaryThe U.S. Food and Drug Administration granted marketing approval to Revolution Medicines for RASONQUE (daraxonrasib). The drug is authorized for patients with metastatic pancreatic adenocarcinoma who progressed on prior therapy or cannot tolerate multiagent chemotherapy. The regulatory clearance marks a significant milestone in oncology by establishing the first commercial broad RAS-targeted inhibitor, validating the company's RAS(ON) inhibitor pipeline.
- XBIDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- XBI closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- XBI price vs. pre-event level
- XBI volume vs. 20-day average
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| XBI | Bullishdisagreed | 168.39 2026-08-26 | -0.10% | -1.79% | -7.33% |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-10-19Zentalis Reports 15.8-Month Median OS for Azenosertib at ESMO CongressXBI ZNTL
- 2026-10-19Viking Therapeutics raises $575M via equity and convertible notesXBI
- 2026-10-19Zentalis Reports 15.8-Month Median OS for Azenosertib at ESMO CongressXBI
- 2026-10-19Viking Therapeutics raises $575M via equity and convertible notesVKTX XBI
- 2026-10-06Spyre Therapeutics Prices $350 Million Public Equity Offering at $85 Per ShareSYRE XBI
- 2026-10-04Genmab Reports 45.9% Response Rate in Phase 2 Ovarian Cancer Antibody-Drug TrialGMAB XBI
- 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17XBI-0.39%
- 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17ADRX XBI-3.04%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.